Animex-On

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Animex-On

Quick Facts

Property Description
Active ingredient Fluoxetine hydrochloride
Form Capsule, Tablet, Oral Solution
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
General purpose Modulation of mood and emotional balance
Origin Synthetic chemical compound

Classification: The Identity of Animex-On as an SSRI

Animex-On is a prescription-only medication defined by its active chemical substance, Fluoxetine hydrochloride. It is formally classified as an antidepressant and belongs to the class of Selective Serotonin Reuptake Inhibitors (SSRIs). This classification means the medicine is specifically designed to influence chemical signaling within the brain to support psychological stability. The SSRI class of drugs is clinically recognized for its efficacy in managing central nervous system conditions where disruptions in serotonin signaling are observed. Animex-On, containing Fluoxetine, is distinguished within the SSRI class due to its long-acting nature and the presence of the active metabolite, Norfluoxetine, which extends its overall pharmacological effect.


Composition, Forms, and General Therapeutic Purpose

The active component, Fluoxetine, is a synthetic chemical compound, manufactured for consistency and purity. The final product, Animex-On, is a single-active ingredient preparation for oral administration, available to patients in several common dosage form(s): standard capsules, tablets, and a liquid oral solution. The primary therapeutic purpose of Animex-On is the sustained modulation of mood and affective states. Its function as an SSRI means it works by increasing the duration that the key neurotransmitter serotonin is available to communicate between nerve cells. By sustaining this increased availability, the medication facilitates the brain's capacity to regulate emotional response and restore equilibrium.

Regulatory References

  1. NIH: Selective Serotonin Reuptake Inhibitors

What side effects are possible with Animex-On?

Possible Side Effects and Safety Information

The safety profile of Animex-On (Fluoxetine) is defined by adverse reactions officially documented and categorized by regulatory authorities, primarily affecting the central nervous, gastrointestinal, and psychiatric systems. The most commonly documented adverse reactions are classified by their frequency, with some occurring in one-tenth or more of patients in clinical trials, while others are less frequent.


Frequency-Classified Adverse Reactions

Classification Selected Documented Effects
Very Common (ge 1/10) Insomnia, Headache, Diarrhea, Nausea, Fatigue
Common (ge 1/100 to < 1/10) Anxiety, Nervousness, Tremor, Dry mouth, Decreased libido, Abnormal ejaculation

Serious Safety Considerations

The official labeling includes explicit warnings for certain rare but clinically significant events. A Boxed Warning is in place concerning an increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults (up to age 24) during short-term studies. The label also documents the risk of developing Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-like reactions, particularly during treatment initiation or dose increases. Other serious documented risks include QT Prolongation and an increased risk of Abnormal Bleeding.


Population-Specific and Use Restrictions

Specific safety considerations are documented for certain populations: geriatric patients are at a higher risk for Hyponatremia (low sodium levels), and caution is required for individuals with hepatic impairment due to prolonged drug clearance. Furthermore, the medicine is contraindicated for use with non-selective Monoamine Oxidase Inhibitors (MAOIs). Use in late pregnancy is associated with a risk of Persistent Pulmonary Hypertension of the Newborn (PPHN).

Overdose and Emergency Response

Overdosing on Animex-On presents a significant risk of severe liver damage (hepatotoxicity), which can lead to life-threatening acute liver failure (ALF) and, in the most severe cases, death or the need for an emergency liver transplant.

Documented Overdose Presentation

The most critical factor is the delayed onset of symptoms. Initial signs of overdose may be mild, non-specific, or even absent for many hours. When symptoms do appear, they may include nausea, vomiting, sweating, and abdominal pain. Even if a person appears to feel well after a suspected overdose, severe, irreversible liver injury may be developing internally.

When to Seek Emergency Medical Help

Immediate medical attention is required for any suspected overdose.

The regulatory profile strongly emphasizes the need to seek emergency help right away, regardless of whether symptoms are present. This urgent action is necessary because the effectiveness of the antidote therapy, which helps prevent or lessen liver damage, is critically dependent on being administered rapidly, ideally within the first eight hours of a single acute ingestion. Do not wait for severe symptoms to appear; call a poison control center or emergency services immediately.

Therapeutic Uses of Animex-On

What Animex-On Treats: Main Uses and Benefits

Animex-On (Fluoxetine) is commonly used to provide supportive symptomatic relief and plays a role in managing emotional stability across several major mental health domains. The therapeutic context for Animex-On is detailed within its therapeutic indications. It is generally applied when symptoms create noticeable functional strain and interfere with an individual’s ability to maintain daily stability.

Animex-On may be part of symptomatic management for conditions such as Major Depressive Disorder, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Bulimia Nervosa, and Premenstrual Dysphoric Disorder (PMDD). It is commonly applied across therapeutic domains where additional symptomatic support is needed, assisting with symptom clusters such as persistent depressed mood, intrusive obsessive thoughts, acute panic attacks, and severe cyclical emotional tension.

“This medication is used to moderate distressing manifestations and provides supportive relief when symptoms interfere with routine activities.”

The key benefit is supporting emotional stability and helping to maintain a more consistent mood, thereby contributing to improved day-to-day comfort and functional stability, especially during periods of heightened symptoms.

Quick Fact: Relief for Key Symptom Clusters
Relief for Depressive Symptoms Supports a more consistent mood and assists with managing associated fatigue.
Relief for Obsessive Symptoms Assists with managing symptoms that create noticeable functional strain.
Relief for Behavioral Symptoms Supports patients during difficult episodes by easing distressing manifestations related to these conditions.

Eligibility and Restrictions for Use

This section outlines the official eligibility and non-eligibility rules for using Animex-On (Fluoxetine), as defined by regulatory authorities like the FDA and EMA.

Populations Strictly Prohibited

Use of Animex-On is contraindicated (absolutely prohibited) in patients with a known hypersensitivity to the medicine. It must not be used concurrently with a Monoamine Oxidase Inhibitor (MAOI), or within the required washout period (14 days before starting Animex-On; 5 weeks after stopping it). Co-administration with Pimozide or Thioridazine, as well as with Linezolid or intravenous Methylene Blue, is also contraindicated.

Age and Condition Restrictions

Population Group Eligibility Status Restriction/Limitation
Pediatric (MDD) Approved Only for patients 8 years and older; safety is not established below this age.
Pediatric (OCD) Approved Only for patients 7 years and older; safety is not established below this age.
Hepatic Impairment Restricted Patients with liver disease require a lower or less frequent dosage due to prolonged drug clearance.
Pregnancy/Lactation Not Recommended Breastfeeding is not recommended. Use in pregnancy is conditional on a risk-benefit assessment due to potential risk of PPHN or neonatal withdrawal symptoms.

Official labeling mandates caution in patients with a history of seizures, pre-existing cardiac conditions that predispose to QT prolongation, and Bipolar Disorder (due to risk of mania activation).

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Animex-On (Fluoxetine) defines restrictions based on its potential for pharmacokinetic and pharmacodynamic interactions with specific medicines and substances.

Contraindicated Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs), Pimozide, Thioridazine, Linezolid, or Intravenous Methylene Blue is formally contraindicated. These prohibitions exist due to the risk of serious adverse events, including QTc prolongation or Serotonin Syndrome.

Pharmacokinetic and Exposure Effects

Animex-On is classified as a potent inhibitor of the CYP2D6 enzyme pathway. This inhibition increases the plasma concentration and exposure of co-administered medicines metabolized by this enzyme, such as Tricyclic Antidepressants (TCAs) and certain Antipsychotics. Pharmacodynamic interactions are noted with other Serotonergic Agents (like Triptans or St. John's Wort), which carry an additive risk of Serotonin Syndrome, and with Drugs that Interfere with Hemostasis (such as NSAIDs), which can potentiate the risk of bleeding.

Mandatory Timing Rules

Mandatory timing requirements exist due to the drug's long half-life: a minimum of five weeks must elapse after stopping Animex-On before starting an MAOI or Thioridazine. Conversely, a minimum of 14 days is required after stopping an MAOI before starting Animex-On. Separately, patients with hepatic impairment may experience reduced clearance, potentially increasing exposure and interaction risks.

Mechanism of Action

Modulating Receptor-Mediated Signaling

Animex-On acts within domains involving receptor- or enzyme-mediated signaling by initiating or suppressing specific signaling sequences. This interaction modifies early molecular steps that shape systemic physiological outcomes, resulting in the modulation of overactive physiological signaling at the cellular level.


Regulating Dysregulated Processes

The drug engages mechanisms that regulate overactive or dysregulated processes that may escalate under certain conditions. Animex-On primarily affects systems where specific transmitters or mediators dominate, modulating the magnitude of excessive mediator activity and establishing a modified equilibrium within targeted pathways.


Influencing Feedback Regulation

Animex-On modulates key pathways associated with heightened physiological responses and is relevant in cascades where multiple layers of pathway activation occur. This engagement influences intrinsic feedback regulation within these pathways, influencing downstream physiological regulation through precise pathway adjustment.

Dosage and Administration Information

How to Use Animex-On

Animex-On (Fluoxetine) is administered exclusively through the oral route, consistent with its formulation as a capsule, tablet, or oral solution. The official dosage and administration patterns are highly dependent on the specific condition being addressed.


Official Dosing and Administration Patterns

Usage Parameter Administration Principle
Route & Forms Oral administration only. Available as capsules, tablets, and a 20 mg/5 mL liquid solution. The oral solution requires accurate measurement using a calibrated device.
Frequency Primarily once daily, typically taken in the morning. A once-weekly delayed-release 90 mg capsule formulation is also available for specific uses.
Timing The medicine may be taken with or without food.
Titration Dosage adjustments (titration) must be performed gradually and slowly, often over several weeks, due to the drug’s long half-life. The initial dose for many adult indications, such as Major Depressive Disorder, is typically 20 mg/day, which may be adjusted up to a maximum of 80 mg/day in certain cases.
Duration Use is typically intended for the long term, with treatment for Major Depressive Disorder often continuing for six months or more to maintain consistency.

Population-Specific Usage

Official labeling includes adjustments for certain populations. For older adults and patients with hepatic impairment, a lower starting dose or a less frequent dosing schedule (e.g., every other day) may be advised due to changes in the body’s clearance rate. Furthermore, the maximum daily dose for older adults is generally lower than the standard adult maximum. Specific pediatric regimens, with lower initial and maximum doses, are approved for certain indications in children and adolescents. If a dose is missed, standard protocols suggest taking the next scheduled dose and skipping the missed one; double doses should not be taken.

Recent Clinical Evidence

Research evidence / Overview of studies for Animex-On

Evidence Base for Animex-On: How Research Was Conducted

This section provides an overview of the clinical research conducted for Animex-On (Fluoxetine), focusing on the structure of the studies and the types of information they provide, as reported in authoritative scientific sources. The core evidence for this medicine comes from official clinical trials, including randomized controlled trials (RCTs). These trials are used in research exploring how symptoms change over time compared to a placebo. Systematic reviews and meta-analyses, which combine the data from multiple primary studies, also contribute to the broader evidence landscape.

The Role of Controlled Trials

The key studies for Animex-On were designed as short-term, placebo-controlled trials. In this research scenario, participants were observed over defined time intervals, and their experiences were compared to those receiving an inactive substance (placebo) under the same study conditions. Research explored short-term symptom changes, primarily using standardized scales to track outcomes related to symptom intensity or variability. The findings describe group patterns observed in the studies and are used to contextualize how patients reported their experience during the study period.


Evidence for Use in Major Depressive Disorder (MDD) and OCD

Animex-On was studied for Major Depressive Disorder (MDD), a condition characterized by fluctuating or episodic manifestations. The primary research for this indication consisted of numerous short-term RCTs. These studies monitored patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning or activity level. Data show patterns related to measured change and global clinical status when compared to placebo. However, the evidence is limited regarding long-term outcomes, as follow-up durations were limited.

Research examined Animex-On for Obsessive-Compulsive Disorder (OCD), a condition associated with acute or disruptive episodes. Studies explored changes in specific outcomes related to symptom intensity, and research suggests that findings were consistent across both adult and pediatric groups studied. Comparative evidence is lacking for complex comorbid populations; long-term effects are not fully established.

Studies Focused on Anxiety and Mood Disorders

Animex-On was studied for Panic Disorder and Premenstrual Dysphoric Disorder (PMDD). For Panic Disorder, studies focused on episodes where symptoms become more noticeable, tracking outcomes describing episodic changes over defined time intervals. For PMDD, research explored symptom changes across multiple menstrual cycles, examining symptom patterns across both continuous and intermittent administration schedules. Certainty remains low regarding the comparative profile of all available doses, and high patient dropout rates were observed in some PMDD studies due to reported experiences.


What Is Still Uncertain About Animex-On Research

Evidence highlights what is known — and what is still uncertain. Data for long-term outcomes, particularly effects measured over many years, are still emerging, as follow-up durations were limited in the core research. Data for certain groups, such as older adults or those with complex co-occurring physical illnesses, remain insufficient. Study results reflect the specific conditions under which they were conducted. Research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Depression in adults: treatment and management - NICE Guideline NG222
  2. Fluoxetine compared with other antidepressants for depression in adults - Cochrane Systematic Review

Frequently Asked Questions (FAQ)

Common questions about Animex-On (FAQ)


Q: How quickly does Animex-On usually start working?

Studies indicate that Animex-On works over a period of time, rather than instantly. Regulatory documents note that the drug’s steady-state concentration—the point where the amount of drug entering the body equals the amount leaving—may take several weeks to be reached. The need for dosage adjustments, or titration, is consistent with its time to reaching stable levels.


Q: How long does the effect of one dose of Animex-On typically last?

The medicine is noted for its long-acting profile. Official information on pharmacokinetics describes the elimination half-life of the active ingredient as typically 1 to 3 days after acute administration. Its major active metabolite, Norfluoxetine, also has a long half-life, which contributes to its prolonged effect.


Q: Are long-term side effects known for Animex-On?

Official clinical trial evidence is based mainly on short-term studies. Regulatory documentation notes that data regarding long-term outcomes, particularly effects measured over many years, are still emerging, as follow-up durations were limited in the core research.


Q: How does Animex-On compare to placebo in clinical studies?

Clinical trials for this medicine included a comparison to an inactive substance, known as a placebo. This research tracked changes in patient-reported outcomes to explore short-term symptom changes. The findings describe group patterns related to measured change in symptoms and overall clinical status when compared against the placebo group.


Q: Is Animex-On the same kind of medicine as [similar drug name]? What's the difference?

Animex-On is formally classified within the Selective Serotonin Reuptake Inhibitor (SSRI) class of medicines. It is generally distinguished from other medicines in this group by its long-acting nature. This is largely due to the presence of its active metabolite, Norfluoxetine, which extends its overall pharmacological effect within the body.


Q: Why do some people call Animex-On a 'daily' medication?

The official administration principle for the standard formulation states that it is administered primarily once daily. This frequency is related to the drug's long half-life, which supports a single daily administration.


Q: What kind of research has been done on Animex-On?

The core evidence base is comprised of official clinical trials, including randomized controlled trials (RCTs). These primary studies are often grouped together in systematic reviews and meta-analyses to provide a comprehensive look at the overall evidence.


Q: Can Animex-On be taken by people with kidney issues?

Regulatory information indicates that studies on the drug’s movement through the body, known as pharmacokinetics, are not significantly affected by renal impairment in certain patients. Specific dose adjustments are not consistently required for certain kidney conditions, but regulatory labeling emphasizes caution.


Q: Does Animex-On cause weight changes?

Clinical trial data indicates that therapy may be associated with modest weight loss during the initial phase of treatment. For patients who continued therapy long-term after remission of depressive symptoms, the reported pattern of weight gain was similar to that observed in individuals taking a placebo.


Q: Why are there different strengths or formulations of Animex-On?

The medicine is available in multiple forms, including capsules, tablets, a liquid solution, and a once-weekly capsule. These variations allow for dosage adjustments, or titration, which may be needed to tailor the treatment to the specific condition being addressed, as well as to accommodate certain patient groups like older adults or children.


Q: What is the typical time frame for clinical trials of Animex-On?

The core research was conducted as short-term, placebo-controlled trials. The duration of these trials varied depending on the condition being studied, typically ranging from approximately 5 weeks up to 16 weeks for acute treatment.


Q: Does Animex-On have any known effect on liver function?

The liver is the primary organ responsible for the drug’s metabolism and clearance from the body. Official warnings note that for patients who have hepatic impairment (liver disease), clearance is reduced and prolonged, which indicates that a lower or less frequent dosing schedule is often used in this population.


Q: Is it normal to feel a bit dizzy when first starting Animex-On?

Official labeling documents adverse reactions that affect the central nervous system, which may include side effects like dizziness and drowsiness. The patient information leaflet contains a complete list of documented effects.


Q: What official warnings exist about driving or operating machinery while taking Animex-On?

Regulatory warnings advise caution regarding operating hazardous machinery or driving until an individual is certain of how the medicine affects their personal performance, as it has the potential to cause central nervous system side effects like dizziness or drowsiness.


Q: Can Animex-On be crushed or split?

The delayed-release capsule and tablet formulations are described as not suitable for cutting, crushing, or chewing. If the oral solution formulation is used, it is intended for accurate measurement and oral administration.


Q: What is the recommended duration of treatment with Animex-On?

Regulatory guidance states that use is typically intended for the long term. For certain conditions like Major Depressive Disorder, treatment often continues for six months or more to maintain consistency, and the long-term usefulness of the medication is typically re-evaluated periodically.


Q: Is Animex-On absorbed differently if you take it in the morning versus the evening?

The medicine is typically administered once daily, often in the morning, and official documents note it may be taken with or without food. While food may cause a slight delay in absorption, it does not appear to affect the total amount of drug that becomes available in the body.


Q: Are there any common supplements that should be avoided while taking Animex-On?

Regulatory warnings note a potential for interaction with St. John's Wort and other serotonergic agents, which carries an additive risk of Serotonin Syndrome. Official sources also advise avoiding supplements such as 5-HTP and L-Tryptophan.


Q: Can Animex-On interact with over-the-counter pain relievers?

Yes, the official regulatory profile notes potential interactions with certain over-the-counter pain relievers. Specifically, co-administration with NSAIDs (Nonsteroidal Anti-inflammatory Drugs), such as ibuprofen, may potentiate the risk of abnormal bleeding.


Q: Can Animex-On be taken with alcohol?

Due to safety risks, the U.S. Food and Drug Administration's official information suggests avoiding or limiting the use of alcohol while being treated with this medication. Alcohol may increase nervous system side effects such as dizziness and drowsiness.


Q: What is the difference between the primary use and secondary uses of Animex-On?

The primary therapeutic purpose of the medicine is the sustained modulation of mood and affective states. The drug is officially approved for the treatment of several conditions, including Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Panic Disorder, and Premenstrual Dysphoric Disorder (PMDD).

How should Animex-On be stored and disposed of?

How to Store and Dispose of Animex-On

Animex-On must be stored according to official regulatory conditions to maintain its stability and effectiveness.

Storage Requirements

Element Official Regulatory Requirement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Environmental Keep the container tightly closed and protect from moisture.
Restrictions Do not refrigerate or freeze the oral solution formulation.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Animex-On must be disposed of as instructed by a healthcare professional or pharmacist. Utilizing drug take-back programs is the preferred method for disposal. The medication should not be flushed down the toilet or poured into a drain unless regulatory documentation specifically allows it.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Animex-On found in:

A-Z Index: